Physician profile
Lara Ries
NPI 1124393228
$1,525.60
in general payments reported to CMS, 2019-2025
19 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $54.84 · 2022: $103 · 2023: $497 · 2024: $289 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $370.78 | 2019-2024 | |
| Abbvie INC. | $219.46 | 2022-2023 | |
| Biogen, INC. | $151.16 | 2019-2025 | Vumerity |
| Kyowa Kirin, INC. | $140.00 | 2024 | Nourianz |
| Genentech, INC. | $112.66 | 2023 | Enspryng |
| Supernus Pharmaceuticals, INC. | $71.25 | 2019-2020 | |
| Allergan, INC. | $61.64 | 2019-2020 | |
| Pfizer INC. | $48.70 | 2023 | |
| Alexion Pharmaceuticals, INC. | $46.79 | 2019-2022 | |
| Acorda Therapeutics, INC | $42.14 | 2019 | |
| Amgen INC. | $41.31 | 2019 | |
| Adamas Pharmaceuticals, INC. | $39.54 | 2019 | |
| Merz North America, INC. | $34.94 | 2019 | |
| Lilly USA, LLC | $34.37 | 2019 | |
| Genzyme Corporation | $31.82 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $27.82 | 2019 | |
| Promius Pharma LLC | $20.64 | 2019 | |
| Ucb, INC. | $18.19 | 2019 | |
| Lundbeck LLC | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lara Ries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.